Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

摘要: Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there some evidence that suggests higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU). This study assessed the optimal dosing strategy irinotecan, along treatment efficacy and safety. A total of 164 patients metastatic cancer progressing after failure on 5-FU or raltitrexed received either (Group A; n=36) 250, 500 m(-2), according to individual patient tolerance B; n=62) based risk factor optimisation C; n=66). There were no complete responses. was trend towards overall response rate in Group B (13%) than Groups (8%) C (9%). Tumour control growth high all three groups: 58% group A, 60% 50% C. 34% 9% able receive m(-2). Median duration time progression significantly longer compared No significant between-group differences any adverse events seen, although small better tolerability B. Individual escalation allow without causing additional toxicity can an appropriate management strategy.